BACTEROMIC

SCOPE FLUIDICS

Investors Day

January 2025

DISCLAIMERS

Niniejsza prezentacja (“Prezentacja”) zawiera podstawowe informacje dotyczące Scope Fluidics S.A. („Spółka”) oraz grupy kapitałowej Scope Fluidics S.A. („Grupa”).

Prezentacja została przygotowana wyłącznie w celu przedstawienia podstawowych informacji o Grupie i jej działalności. Prezentacja nie przedstawia pełnych danych dotyczących działalności Grupy, jej kondycji finansowej, sytuacji majątkowej i prawnej, które mogą być wymagane w celu podjęcia decyzji inwestycyjnej dotyczącej Grupy lub instrumentów finansowych podmiotów do niej należących. Spółka podjęła środki w celu zapewnienia, że zaprezentowane dane są w pełni wiarygodne, jakkolwiek nie mogą i nie powinny być jako takie traktowane. Wszystkie przewidywania, opinie i projekcje zawarte w Prezentacji łącznie z projekcjami, opiniami oraz przewidywaniami Spółki zostały przygotowane w ramach wykonywania zwykłych czynności analitycznych i nie należy ich traktować jako informacji zatwierdzonych przez jakikolwiek podmiot trzeci. Mimo podjęcia środków mających na celu zapewnienie, że fakty wskazane w Prezentacji są prawdziwe, a przewidywania, opinie i prognozy są wiarygodne i zasadne, Spółka nie weryfikowała ich kompletności ani trafności. W konsekwencji ani Spółka ani żaden z jej akcjonariuszy i doradców, ich podmiotów powiązanych, członków organów i pracowników nie ponosi odpowiedzialności, na jakiejkolwiek podstawie, za treści zawarte w Prezentacji.

Przy podejmowaniu decyzji inwestycyjnych, czy też działając w jakimkolwiek innym celu, nie należy opierać się na informacjach zawartych w Prezentacji, w tym w zakresie ich prawdziwości, rzetelności i zupełności. Żaden z wymienionych wyżej pomiotów nie uznaje swojej odpowiedzialności na jakiejkolwiek podstawie za jakiekolwiek szkody wynikające z użycia niniejszego dokumentu i informacji w nim zawartych. Oświadczeń zawartych w Prezentacji nie należy traktować jako zapewnień lub gwarancji Spółka lub jako zobowiązań czy obietnic dotyczących przyszłych wyników finansowych czy operacyjnych Grupy. Treść Prezentnacji nie stanowi ani nie powinna być traktowana jako porada inwestycyjna, prawna lub podatkowa. Odbiorca Prezetacji powinien samodzielnie uzyskać odpowiednią poradę inwestycyjną, prawną bądź podatkową.

Prezentacja nie stanowi oferty, w szczególności w rozumieniu ustawy z dnia 29 lipca 2005 roku o ofercie publicznej i warunkach wprowadzania instrumentów finansowych do zorganizowanego systemu obrotu oraz o spółkach publicznych (Dz.U. t.j. 2013.1382 z późn. zm.) lub ustawy z dnia 23 kwietnia 1964 r. kodeks cywilny (Dz.U. t.j. 2014.121 z późn. zm.), rekomendacji lub zaproszenia do zapisywania się lub zakupu obligacji. Ani Prezentacja ani żadna jej część nie stanowi jakiejkolwiek umowy lub jakiegokolwiek zobowiązania dotyczącego wykonania takiej umowy.

Spółka zastrzega sobie prawo do dokonania zmian lub uzupełniania Prezentacji w każdym momencie, jakkolwiek nie jest do tego zobowiązana, podobnie jak nie jest zobowiązana do dokonywania jakichkolwiek aktualizacji lub poprawek treści Prezentacji, ani do dostarczania dodatkowych informacji o Spółce ani Grupie.

UNIQUE COMBINATION OF COMPETENCIES IN TECHNOLOGY, OPERATIONS AND FINANCIAL AREAS

MANAGEMENT BOARD OF SCOPE FLUIDICS

MARCIN IZYDORZAK

VICE PRESIDENT

- Co-founder of Scope Fluidics
- Responsible for clinical trials, IP, production and regulatory areas
- Gained experience in technology companies, scientific institutes and pharmaceutical companies

PROF. PIOTR GARSTECKI

CEO

- Co-founder of Scope Fluidics
- Responsible for development of innovative technologies and building the organization
- Experience in scientific and technological projects in Poland and in the USA, specialized in soft matterphysics and microfluidic technologies

SZYMON RUTA

VICE PRESIDENT, CFO

- Responsible for financial division, investor relations and M&A transactions
- Experienced in managing of capital groups, cooperation with capital markets and execution of M&A transactions

SCOPE FLUIDICS
Agenda for today

BACTEROMIC

1. **Scope Fluidics**
2. BACTEROMIC
3. Tours and side presentations
   - ✓ BACTEROMIC – walk-through
   - ✓ BACTEROMIC – labs & manufacturing short presentation
   - ✓ BACTEROMIC – presentation of the system
   - ✓ Scope Discovery and PMR – short presentetions
4. Edocera
5. Hybolic

SCOPE FLUIDICS

Venture Studio
- our values and vision for success

BACTEROMIC

We address **global challenges in healthcare** and develop technologies with clear, significant impact.

We aim at +USD 10^9 markets and develop technologies that can readily be leveraged by large, multinational and global med-tech operators.

VENTURE STUDIO BUSINESS MODEL

Corporate structure supports execution of M&A transactions

BACTEROMIC

Each project in Scope Fluidics' Group is **developed in a separate, legal entity (SPV)**

Each subsidiary is focused on the R&D activities and has the full ownership of all the IP relevant to its project, employment, commercial contracts, and all relevant certifications

Scope Fluidics provides SPVs with back-office functions, such as HR, finance, reporting, legal, regulatory, etc.

Scope Fluidics

100% ownership of the SPVs

Sold to Bio-Rad Laboratories August 2022			
SUBSIDIARY #1	**SUBSIDIARY #2**	**SUBSIDIARY #3**	**SUBSIDIARY #4**
Curiosity Diagnostics	BACTEROMIC **Antimicrobial Susceptibility Testing**	**EDOCERA** **Prevention and ongoing diagnostics for patients at risk of stroke**	**HYBOLIC** **Comprehensive solution for patients with metabolic syndrome**
Started in 2012	**Started in 2017**	**Started in 2024**	**Started in 2024**

Know-how and capacity to bring products from identification of challenge to market access.

140 employes, 20+ PhDs, 3 SPVs, Scope Discovery

After 15 years on the market we have all specialities on board for development of technologies from zero to launch of products on the market, together with an extensive network of liesons in the industry and investment ecosystem



15 Years of Systematic Growth: Building an Even Stronger Future

From a 10k PLN start-up to a largest med-tech venture studio in CEE

2010 Founded for PLN 10k

2010-2015 Two generations of BlueBox, EUR 6m turnover

2012 Launch of Curiosity Diagnostics

2017 Founding of the Bacteromic company

2017 New Connect listing

2022 Development and sale of PCR I ONE

2023 Listing on the main market of WSE

2023 Launch of Scope Discovery

2024 Launch of Edocera and Hybolic SPVs

2025 BACTEROMIC in IVDR certification process, market launch

SCOPE FLUIDICS

Financial track record – outstanding return on investment and dynamic outlook for future developments.

BACTEROMIC

Raised
~USD 10m
(< 50 mPLN)

USD 130m revenue from sales of PCR I One

USD 100m market cap (**10x** since IPO)

USD 50m dividend payed out in 2023

BACTEROMIC developed to the **pre IVDR stage**

Stable cash position

SCOPE DISCOVERY
Projects Pipeline

Scope Discovery

29 projects assessed:
- 15 projects closed
- 12 ongoing projects
- 2 SPVs launched



Number of dots does not represent actual numer of projects

SCOPE FLUIDICS

Key value-building stages

Launching product on the market increases its attractiveness and value

$
Concept

Strong
proof-of-concept
proposition

$$
Technology

Team of professionals
Laboratory
Patent protection
Clinical performance
Certification
Manufacturing capacity
Compliance (ISO)

$$$$
Market traction

Market feedback (Early Access)
First clients
Revenue
Profitability



SCOPE FLUIDICS

Scope Fluidics Strategy

BACTEROMIC

1 **By the end of 2025**
having at least five new projects in the portfolio, including **at least two** in the form of **special purpose vehicles**

2 **By the end of 2028**
Closing at least two **strategic transactions**

3 **In the period of 2029-2033**
readiness to carry out **at least one strategic transaction on an annual average**

STRATEGIC TRANSACTIONS:

1. **Sale of all shares in special purpose vehicles** developing breakthrough technologies to strategic industry investors
2. **Sale of part of existing or newly created shares in Special Purpose Vehicles** developing breakthrough technologies to strategic industry or financial investors

SCOPE FLUIDICS

Agenda for today

BACTEROMIC

1. Scope Fluidics
2. **BACTEROMIC**
3. Tours and side presentations
   - ✓ BACTEROMIC – walk-through
   - ✓ BACTEROMIC – labs & manufacturing short presentation
   - ✓ BACTEROMIC – presentation of the system
   - ✓ Scope Discovery and PMR – short presentetions
4. Edocera
5. Hybolic

Leading the Next Generation of AST solutions

Fastest access to precision antibiotic therapies

High-content, automated antibiotic susceptibility testing with rapid, same-shift results

BACTEROMIC

Rapid | Versatile | Super Informative | Cost-effective

BACTEROMIC

The best system for the evolving Antibiotic Susceptibility Testing market

Antibiotic resistance
– one of biggest threats to human health



September 26th, 2024

Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) **High-Level Meeting on Antimicrobial Resistance (AMR)**, committing to a clear set of targets and actions, including **reducing the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance (AMR) annually by 10% by 2030**.

Antibiotic resistance
– one of biggest threats to human health



World Health Organization

September 26th, 2024

Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) **High-Level Meeting on Antimicrobial Resistance (AMR)**, committing to a clear set of targets and actions, including **reducing the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance (AMR) annually by 10% by 2030**.

What is Antibiotic Susceptibility Test (AST)?

BACTEROMIC



VS

Bacteria Antibiotic

1

Minimum inhibitory concentration (MIC)

The smallest concentration of antibiotic inhibiting bacterial growth

2

Susceptibility Category

S - Susceptible

I – Intermediate

(Susceptible, increased exposure)

R - Resistant

AST Report

Patient: John Kowalski

Bacteria: Escherichia coli

Antibiotics	MIC	Susceptibility Category
Amoxicillin	4 µg/ml	S
Cephazolin	0,25 µg/ml	S
Ceftazidime	16 µg/ml	R
…	…	…

Information used in severe/complex cases

Mandatory information

DOCTOR ADMINISTERS TIMELY AND PRECISE THERAPY

Market analysis

Customer options

BACTEROMIC

MANUAL

Disk diffusion

- The cheapest
- Well known

- Laborious
- Only Category

E-tests

- Cheap
- MIC

- Laborious
- Time-consuming



Broth microdilution

- Golden standard
- MIC

- Laborious
- Expensive

AUTOMATED

Automated
(standard)

- High-throughput
- Automated

- Limited drug coverage
- Expensive

Automated
(specialized)

- New applications
- Rapid

- Very limited drug coverage
- The most expensive

Lab manager

No solution addresses all my needs.

User Advantages

User-centric design and compliance



Analyzer:

- **Capacity for 60 Cartridges** – high throughput with random access
- <6h Time to Result
- LIS connectivity

Filling Device:

- Quick, fully automated procedure of inoculation & sealing for up to 10 Cartridges (~5 min)

Simple and standardized AST workflow

Diluted **Isolate / PBC solution** is pipetted onto the cartridge



<1 min

Up to 10 cartridges in parallel, automatically filled & sealed

<5 min

Automated AST on up to **60 cartridges**

<6 hours

AST results in LIS

ACTIONABLE AST RESULTS FOR GUIDED ANTIBIOTIC THERAPY

NO NEED FOR ID BEFORE TEST **– can be provided during or after AST for results interpretation**



BACTEROMIC

Unmatched Data Density with 640 Incubation Chambers

The widest antibiotics menu – up to 60 antibiotics with real MICs in a single assay



BACTEROMIC offers **640 incubation chambers**, the highest in the industry, enabling **rapid AST across all antibiotics in a single assay**, reducing the time to treatment.

- **Real MIC** quantitative antibiograms
- **The broadest drug coverage**
- Single system for **PBC and Isolates**
- **Cost-effective** manufacturing
- **High** throughput

The highest information content

The most comprehensive & precise AST information



640 INCUBATION CHAMBERS

TO PROVIDE THE MOST COMPREHENSIVE AST PANEL:

up to 60
antibiotics
in a single Panel

UNPRECEDENTED INFORMATION CONTENT

All clinically-relevant antibiotics in a single Panel:

- **Single-product portfolio** for each sample type
- **The most effective** treatment **after a single test** incl. **alternatives** for conflicted default antibiotics
- Minimizes **risk of human error** and potential **need for retesting – minimizing health complications & treatment time**
- Manufacturing and operational synergies

up to 14
dilutions
per antibiotic

GOLDEN STANDARD TWO-FOLD DILUTION SERIES

Clinical argument – successful targeted antibiotics treatment even in the most severe and complex infections

Performance – detailed resistance mechanism analysis:
- SIR category & actual MIC level
- screening for resistance mechanisms
- confirmation of the presence of resistance mechanism

Future-proof – broad golden standard double-dilutions series allow continous compliance with EUCAST/CLSI recommendations even in major breakpoints updates

Market analysis

Addressing critical global healthcare challenge

Opportunity to serve a growing and evolving market demand

BACTEROMIC

Culture isolates

Global AST diagnostics market (USD bn)

- **"AMR could cause 10 million deaths annually by 2050"** *(Jim O'Neill Report)*
- **"Currently, AMR is linked to 1.27 million deaths each year"** *(Chris Murray, The Lancet, 2022)*



Blood culture

Global sepsis diagnostics market (USD bn)

- **"Sepsis accounts for 20% of all deaths globally"** *(Global Sepsis Alliance, 2020).*
- **"Rapid AST is critical for targeted sepsis therapies."**



Fortune Business Insights, CoherentMarketInsights, Mordor Intelligence, Grand View Research

Competition

Status quo – separate systems with complex product portfolios

BACTEROMIC

Isolates AST

Slow, complex product portfolio, only for isolates





Manufacturing	Purchase	Storage	Usage	
Portfolios of 10-15+ panels with limited antibiotics menus	**Ordering multiple panel types** (prediction of future lab work needed)	**Stocking multiple panels**	**Risk of error in choice of panel**	**Risk of repeated testing** (prolonged hospital stay & increased treatment costs)

PBC AST

Different system and workflow, only for PBC, separate panels for G-/G+

Manufacturing	Purchase	Storage	Usage	
Portfolios of 1-4 panels with limited antibiotics menus	**Ordering panels for different system**	**Stocking panels for multiple systems**	**Risk of lack of constructive result due to limited antibiotic menu**	**Risk of repeated testing** jeopardizing patient outcomes

Market analysis

AST market requirements

BACTEROMIC

Culture isolates	Single dilution sample preparation (ease of use)	All relevant antibiotics in one test (broad drug coverage)	↑ 30-150 tests/day (high volumes)	↓ 5-30 € per panel (low margin)	• High throughput • Low price
Blood culture	Single dilution sample preparation (ease of use)	All relevant antibiotics in one test (broad drug coverage)	↓ 3-15 tests/day (low volumes)	↑ 50-200 € per panel (high margin)	• Fast

BACTEROMIC

AST market needs future-proof, informative, rapid system

that offers synergies across isolate and PBC market segments

Market analysis

Automatic AST market

BACTEROMIC

	Standard AST (16-24 h)	Rapid AST (2-8 h)
Culture isolates		
Blood culture	No market	

Common platform for two markets

Simplifying and maximizing AST value chain

Same Cartridge architecture & analyzers for both PBC and Isolates. Information capacity minimizes number of distinct panels.

Single system for Isolates and PBC

Isolates AST
same Cartridge architecture with all antibiotics covered

→ Less storage space, single shelf life → Compatible with Bacteromic analyzers → Fastest access to precision antibiotic therapies

Same supply chain

Same manufacturing



Common Logistics & storage chain

Shared installed base

complete information



PBC AST
same Cartridge architecture with all antibiotics covered

→ Less storage space, single shelf life → Compatible with Bacteromic analyzers → Fastest access to precision antibiotic therapies

Updated goals for BACTEROMIC

ESPI 05/2024 – may 2024

Commercial introduction of BACTEROMIC system to the international market:

a) Obtaining contracts for purchase of the BACTEROMIC system
b) IVDR certification of the BACTEROMIC system's components
c) Securing external manufacturing capacity for the commercial Panels' production



Expanding the product portolio:

a) Development of new products
b) Certification of new products

FAST detection – preliminary R&D results

Goal:

same-shift AST results

6-8h

time-to-result

- Bacteromic is ready for rapid AST of clinically applicable antibiotic-bacteria combinations under IVDR standards
- To be implemented for PBC, as well as Isolates
- Results of Panel FAST after analytical performance evaluation on Isolates shows:

Bacteria	TTR [hours]	Antibiotics
Acinetobacter spp.	6	8
Enterobacterales group	6	22
Enterococcus spp.	6	9
Pseudomonas spp.	8	7
Staphylococcus spp.	6	19

- Status: in preparation for IVDR certification

IVDR certification of the BACTEROMIC system's components

Agreement with Notified Body (Panel UNI and Interpreter)

Signed in September 2024

Start of Clinical Performence Evaluation

Started in November 2024

IVDR certification

Planned in H2'2025

MANUFACTURING

Securing external manufacturing capacity

ANALYZER & FILLING DEVICE

November 2023 - launched cooperation with BIT
German OEM partner specializing in electronic hardware assembly

OEM CARTRIDGE PRODUCTION LINE:
several hundred k/year

November 2024 - cooperation with TE Connectivity for design and setup of semi-automated line in Spain

Launch planned by the end of 2025

Total est. budget: EUR 1m

Intellectual Property – patent portfolio

METHOD AND SYSTEM FOR RAPIDLY TESTING ANTIMICROBIAL SUSCEPTIBILITY

Rapid signal analysis method of determining the minimum inhibitory concentration (MIC) based on standard measurements in the shortest possible time to date

METHOD AND SYSTEM FOR PREDICTION OF MICROORGANISM GROWTH USING ARTIFICIAL INTELLIGENCE

The computer-implemented method for real-time prediction of microorganism growth or growth inhibition of a microorganism inoculum using artificial intelligence (AI)

MICROFLUIDIC CHIP

The invention is intended for microbiological testing cards, particularly for microbial identification and antimicrobial susceptibility testing (AST)

INCUBATION SEGMENT WITH AN UNVENTED GAS CAVITY IN A MICROFLUIDIC CHIP

The object of the invention is the geometry of a single incubation segment in a microfluidic chip, suitable for microbiological research

A SYRINGE-PLUG AND A CARTRIDGE FOR ANALYTIC ASSAYS COMPRISING SUCH A SYRINGE-PLUG

Provided for sealing a sample chamber of a cartridge for analytic assays, comprises a tank pre-filled with a non-aquatic liquid

Recent updates:

January 2024 – US patent granted for „Microfluidic Chip"

June 2024 – US patent granted for „Incubation segment in microfluidic chip"

August 2024 – CN patent granted for „Incubation segment in microfluidic chip"

October 2024 – CN patent granted for „Method and System for rapid AST"

Further IP processes in progress

Patent Portfolio

BACTEROMIC

MICROFLUIDIC CHIP

METHOD AND SYSTEM FOR RAPIDLY TESTING ANTIMICROBIAL SUSCEPTIBILITY

INCUBATION SEGMENT WITH AN UNVENTED GAS CAVITY IN A MICROFLUIDIC CHIP



METHOD AND SYSTEM FOR PREDICTION OF MICROORGANISM GROWTH USING ARTIFICIAL INTELLIGENCE

A SYRINGE-PLUG AND A CARTRIDGE FOR ANALYTIC ASSAYS COMPRISING SUCH A SYRINGE-PLUG



M&A activity in 2024

January
San Francisco

JP Morgan Healthcare Conference

April
Barcelona

ECCMID

May
Luxembourg

EIB Alumn Event

June
London

JP Morgan Healthcare Symposium

July
Chicago

ADLM

November
Dusseldorf

MEDICA

November
London

Jefferies Healthcare Conference

J.P.Morgan
Jefferies
TD Cowen
BANK OF AMERICA
P/W/P PERELLA WEINBERG PARTNERS
KPMG